Characterizing the Biological Roles of the Arenavirus Exoribonuclease (exoN) in a Tri-Segmented Pichinde Virus System
Viruses · 2026-11-09 · 18 (11) · 1246
DOI: 10.3390/v18111246 ↗Abstract
Arenaviruses, such as Lassa virus (LASV) and Junin virus (JUNV), cause severe and often lethal hemorrhagic fevers, for which there are no FDA-approved vaccines or effective therapeutics. The viral nucleoprotein (NP) contains a 3′-5′ exoribonuclease (exoN) domain to suppress type I interferon (IFN-I) induction. However, the precise biological roles of the NP exoN during infection remain poorly characterized for highly pathogenic arenaviruses due to biosafety constraints and challenges in generating viable exoN mutants. Utilizing a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) suitable for BSL-2 research, we generated two exoN-deficient GFP reporter viruses, (NPm1)-G and (NPm2)-G, by mutating key catalytic residues, and inserted JUNV NP as a transgene within the mutant backbones. All recombinant viruses replicated efficiently in IFN-deficient Vero cells. In IFN-competent A549 cells, all viruses except for the wild-type reporter virus rP18tri-G failed to undergo multicycle replication, consistent with their differential inhibition of IFN-I responses. In contrast to rP18tri-G, which effectively suppressed IFN-I induction throughout the infection time course, exoN-deficient viruses induced robust early IFN-I responses, whereas expressing JUNV NP as a transgene suppressed early IFN-I induction at 16 hpi but failed to sustain suppression at later time points. Further examination during the first round of viral replication in A549 cells demonstrated that the absence of exoN activity is associated with markedly reduced viral gene expression and decreased infectious particle production. Together, these data demonstrate an essential role for NP exoN in mediating IFN-I suppression and suggest its biological functions in viral gene expression and infectious particle production within IFN-competent cells, highlighting its potential as a broad-spectrum therapeutic target.
EUVIMED